- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Drug Delivery
Volume 2011 (2011), Article ID 296151, 12 pages
The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier
1Department of Medicine, UCLA, Warren Hall 13-164, 900 Veteran Avenue, Los Angeles, CA 90024, USA
2ArmaGen Technologies, Inc., Santa Monica, CA 90401, USA
Received 5 July 2011; Revised 4 September 2011; Accepted 4 September 2011
Academic Editor: Abdelwahab Omri
Copyright © 2011 Ruben J. Boado and William M. Pardridge. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- W. M. Pardridge, “Drug and gene delivery to the brain: the vascular route,” Neuron, vol. 36, no. 4, pp. 555–558, 2002.
- K. W. Mok, A. M. Lam, and P. R. Cullis, “Stabilized plasmid-lipid particles: factors influencing plasmid entrapment and transfection properties,” Biochimica et Biophysica Acta, vol. 1419, no. 2, pp. 137–150, 1999.
- N. Shi and W. M. Pardridge, “Noninvasive gene targeting to the brain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 13, pp. 7567–7572, 2000.
- R. J. Boado, “Blood-brain barrier transport of non-viral gene and RNAi therapeutics,” Pharmaceutical Research, vol. 24, no. 9, pp. 1772–1787, 2007.
- A. P. Byrnes, J. E. Rusby, M. J. Wood, and H. M. Charlton, “Adenovirus gene transfer causes inflammation in the brain,” Neuroscience, vol. 66, no. 4, pp. 1015–1024, 1995.
- M. J. Wood, H. M. Charlton, K. J. Wood, K. Kajiwara, and A. P. Byrnes, “Immune responses to adenovirus vectors in the nervous system,” Trends in Neurosciences, vol. 19, no. 11, pp. 497–501, 1996.
- J. G. Smith, S. E. Raper, E. B. Wheeldon et al., “Intracranial administration of adenovirus expressing HSV-TK in combination with ganciclovir produces a dose-dependent, self-limiting inflammatory response,” Human Gene Therapy, vol. 8, no. 8, pp. 943–954, 1997.
- M. J. Driesse, A. J. Vincent, P. A. Sillevis Smitt et al., “Intracerebral injection of adenovirus harboring the HSVtk gene combined with ganciclovir administration: toxicity study in nonhuman primates,” Gene Therapy, vol. 5, no. 8, pp. 1122–1129, 1998.
- M. J. Driesse, M. C. Esandi, J. M. Kros et al., “Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity,” Gene Therapy, vol. 7, no. 16, pp. 1401–1409, 2000.
- U. Herrlinger, C. M. Kramm, K. S. Aboody-Guterman et al., “Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector,” Gene Therapy, vol. 5, no. 6, pp. 809–819, 1998.
- M. M. McMenamin, A. P. Byrnes, H. M. Charlton, R. S. Coffin, D. S. Latchman, and M. J. Wood, “A γ34.5 mutant of herpes simplex 1 causes severe inflammation in the brain,” Neuroscience, vol. 83, no. 4, pp. 1225–1237, 1998.
- R. A. Dewey, G. Morrissey, C. M. Cowsill et al., “Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials,” Nature Medicine, vol. 5, no. 11, pp. 1256–1263, 1999.
- M. S. Lawrence, H. G. Foellmer, J. D. Elsworth et al., “Inflammatory responses and their impact on β-galactosidase transgene expression following adenovirus vector delivery to the primate caudate nucleus,” Gene Therapy, vol. 6, no. 8, pp. 1368–1379, 1999.
- Y. Stallwood, K. D. Fisher, P. H. Gallimore, and V. Mautner, “Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients,” Gene Therapy, vol. 7, no. 8, pp. 637–643, 2000.
- K. Kajiwara, A. P. Byrnes, Y. Ohmoto, H. M. Charlton, M. J. Wood, and K. J. Wood, “Humoral immune responses to adenovirus vectors in the brain,” Journal of Neuroimmunology, vol. 103, no. 1, pp. 8–15, 2000.
- H. Matsui, L. G. Johnson, S. H. Randell, and R. C. Boucher, “Loss of binding and entry of liposome-DNA complexes decreases transfection efficiency in differentiated airway epithelial cells,” Journal of Biological Chemistry, vol. 272, no. 2, pp. 1117–1126, 1997.
- L. G. Barron, L. S. Uyechi, and F. C. Szoka Jr., “Cationic lipids are essential for gene delivery mediated by intravenous administration of lipoplexes,” Gene Therapy, vol. 6, no. 6, pp. 1179–1183, 1999.
- G. Osaka, K. Carey, A. Cuthbertson et al., “Pharmacokinetics, tissue distribution, and expression Efficiency of plasmid [33P]DNA following intravenous administration of DNA/cationic lipid complexes in mice: use of a novel radionuclide approach,” Journal of Pharmaceutical Sciences, vol. 85, no. 6, pp. 612–618, 1996.
- W. M. Pardridge, “Gene targeting in vivo with pegylated immunoliposomes,” Methods in Enzymology, vol. 373, pp. 507–528, 2003.
- N. Shi, R. J. Boado, and W. M. Pardridge, “Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes,” Pharmaceutical Research, vol. 18, no. 8, pp. 1091–1095, 2001.
- N. Shi, Y. Zhang, C. Zhu, R. J. Boado, and W. M. Pardridge, “Brain-specific expression of an exogenous gene after i.v. administration,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 22, pp. 12754–12759, 2001.
- Y. Zhang, F. Calon, C. Zhu, R. J. Boado, and W. M. Pardridge, “Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism,” Human Gene Therapy, vol. 14, no. 1, pp. 1–12, 2003.
- Y. Zhang, Y. F. Zhang, J. Bryant, A. Charles, R. J. Boado, and W. M. Pardridge, “Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer,” Clinical Cancer Research, vol. 10, no. 11, pp. 3667–3677, 2004.
- D. Papahadjopoulos, T. M. Allen, A. Gabizon et al., “Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 24, pp. 11460–11464, 1991.
- A. Gabizon and D. Papahadjopoulos, “Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 18, pp. 6949–6953, 1988.
- R. J. Boado, Y. F. Zhang, Y. Zhang, and W. M. Pardridge, “Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier,” Biotechnology and Bioengineering, vol. 96, no. 2, pp. 381–391, 2007.
- F. Schlachetzki, Y. Zhang, R. J. Boado, and W. M. Pardridge, “Gene therapy of the brain: the trans-vascular approach,” Neurology, vol. 62, no. 8, pp. 1275–1281, 2004.
- Y. Zhang, R. J. Boado, and W. M. Pardridge, “Marked enhancement in gene expression by targeting the human insulin receptor,” Journal of Gene Medicine, vol. 5, no. 2, pp. 157–163, 2003.
- Y. Zhang, R. J. Boado, and W. M. Pardridge, “In vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats,” Journal of Gene Medicine, vol. 5, no. 12, pp. 1039–1045, 2003.
- Y. Zhang, F. Schlachetzki, Y. F. Zhang, R. J. Boado, and W. M. Pardridge, “Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter,” Human Gene Therapy, vol. 15, no. 4, pp. 339–350, 2004.
- Y. Zhang, H. Y. Lee, R. J. Boado, and W. M. Pardridge, “Receptor-mediated delivery of an antisense gene to human brain cancer cells,” Journal of Gene Medicine, vol. 4, no. 2, pp. 183–194, 2002.
- C. F. Xia, Y. Zhang, Y. Zhang, R. J. Boado, and W. M. Pardridge, “Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology,” Pharmaceutical Research, vol. 24, no. 12, pp. 2309–2316, 2007.
- C. Chu, Y. Zhang, R. J. Boado, and W. M. Pardridge, “Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation,” Pharmaceutical Research, vol. 23, no. 7, pp. 1586–1590, 2006.
- Y. Zhang, F. Schlachetzki, and W. M. Pardridge, “Global non-viral gene transfer to the promate brain following intravenous administration,” Molecular Therapy, vol. 7, no. 1, pp. 11–17, 2003.
- Y. Zhang, F. Schlachetzki, J. Y. Li, R. J. Boado, and W. M. Pardridge, “Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer,” Molecular Vision, vol. 9, pp. 465–472, 2003.
- Y. Zhang, Y. Wang, R. J. Boado, and W. M. Pardridge, “Lysosomal enzyme replacement of the brain with intravenous non-viral gene transfer,” Pharmaceutical Research, vol. 25, no. 2, pp. 400–406, 2008.
- Y. A. Ioannou, “Gene therapy for lysosomal storage disorders with neuropathology,” Journal of the American Society of Nephrology, vol. 11, no. 8, pp. 1542–1547, 2000.
- W. C. Aird, “Phenotypic heterogeneity of the endothelium I. Structure, function, and mechanisms,” Circulation Research, vol. 100, no. 2, pp. 158–173, 2007.
- A. Bosch, E. Perret, N. Desmaris, D. Trono, and J. M. Heard, “Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer,” Human Gene Therapy, vol. 11, no. 8, pp. 1139–1150, 2000.
- M. M. Mouradian and T. N. Chase, “Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications,” Experimental Neurology, vol. 144, no. 1, pp. 51–57, 1997.
- R. Mandil, E. Ashkenazi, M. Blass et al., “Protein kinase Cα and protein kinase Cδ play opposite roles in the proliferation and apoptosis of glioma cells,” Cancer Research, vol. 61, no. 11, pp. 4612–4619, 2001.
- I. Nagatsu, H. Ichinose, M. Sakai, K. Titani, M. Suzuki, and T. Nagatsu, “Immunocytochemical localization of GTP cyclohydrolase I in the brain, adrenal gland, and liver of mice,” Journal of Neural Transmission, vol. 102, no. 3, pp. 175–188, 1995.
- O. Hwang, H. Baker, S. Gross, and T. H. Joh, “Localization of GTP cyclohydrolase in monoaminergic but not nitric oxide-producing cells,” Synapse, vol. 28, no. 2, pp. 140–153, 1998.
- M. Shimoji, K. Hirayama, K. Hyland, and G. Kapatos, “GTP cyclohydrolase I gene expression in the brains of male and female hph-1 mice,” Journal of Neurochemistry, vol. 72, no. 2, pp. 757–764, 1999.
- I. Nagatsu, R. Arai, M. Sakai et al., “Immunohistochemical colocalization of GTP cyclohydrolase I in the nigrostriatal system with tyrosine hydroxylase,” Neuroscience Letters, vol. 224, no. 3, pp. 185–188, 1997.
- N. Kaneda, T. Sasaoka, K. Kobayashi et al., “Tissue-specific and high-level expression of the human tyrosine hydroxylase gene in transgenic mice,” Neuron, vol. 6, no. 4, pp. 583–594, 1991.
- N. Min, T. H. Joh, K. S. Kim, C. Peng, and J. H. Son, “5' Upstream DNA sequence of the rat tyrosine hydroxylase gene directs high-level and tissue-specific expression to catecholaminergic neurons in the central nervous system of transgenic mice,” Molecular Brain Research, vol. 27, no. 2, pp. 281–289, 1994.
- C. F. Xia, C. Chu, J. Li et al., “Comparison of cDNA and genomic forms of tyrosine hydroxylase gene therapy of the brain with Trojan horse liposomes,” Journal of Gene Medicine, vol. 9, no. 7, pp. 605–612, 2007.
- Y. F. Zhang, R. J. Boado, and W. M. Pardridge, “Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes,” Pharmaceutical Research, vol. 20, no. 11, pp. 1779–1785, 2003.
- T. Skjørringe, T. Gjetting, and T. G. Jensen, “A modified protocol for efficient DNA encapsulation into pegylated immunoliposomes (PILs),” Journal of Controlled Release, vol. 139, no. 2, pp. 140–145, 2009.
- Y. T. Ko, R. Bhattacharya, and U. Bickel, “Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting,” Journal of Controlled Release, vol. 133, no. 3, pp. 230–237, 2009.
- A. Schnyder, S. Krähenbühl, J. Drewe, and J. Huwyler, “Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects,” Journal of Drug Targeting, vol. 13, no. 5, pp. 325–335, 2005.
- W. M. Pardridge, J. L. Buciak, and P. M. Friden, “Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo,” Journal of Pharmacology and Experimental Therapeutics, vol. 259, no. 1, pp. 66–70, 1991.
- J. H. Lee, B. Engelhardt, J. Lesley, U. Bickel, and W. M. Pardridge, “Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse,” Journal of Pharmacology and Experimental Therapeutics, vol. 292, no. 3, pp. 1048–1052, 2000.
- R. J. Boado, Y. Zhang, Y. Wang, and W. M. Pardridge, “Engineering and expression of a chimeric transferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse,” Biotechnology and Bioengineering, vol. 102, no. 4, pp. 1251–1258, 2009.
- B. Gupta, T. S. Levchenko, and V. P. Torchilin, “TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice,” Oncology Research, vol. 16, no. 8, pp. 351–359, 2007.
- V. P. Chekhonin, Y. A. Zhirkov, O. I. Gurina et al., “PEGylated immunoliposomes directed against brain astrocytes,” Drug Delivery, vol. 12, no. 1, pp. 1–6, 2005.
- S. Kawakami, F. Yamashita, K. Nishida, J. Nakamura, and M. Hashida, “Glycosylated cationic liposomes for cell-selective gene delivery,” Critical Reviews in Therapeutic Drug Carrier Systems, vol. 19, no. 2, pp. 171–190, 2002.
- T. Montier, P. Delépine, T. Benvegnu et al., “Efficient gene transfer into human epithelial cell lines using glycosylated cationic carriers and neutral glycosylated co-lipids,” Blood Cells, Molecules, and Diseases, vol. 32, no. 2, pp. 271–282, 2004.
- W. M. Pardridge, Y. S. Kang, J. L. Buciak, and J. Yang, “Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate,” Pharmaceutical Research, vol. 12, no. 6, pp. 807–816, 1995.